B. Riley downgraded Madrigal Pharmaceuticals to Sell from Neutral with a $155 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MDGL:
- Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Madrigal Pharmaceuticals reports inducement grants under Nasdaq listing rule
- Cantor biotech/biopharma analysts to hold analyst/industry conference call
- Biotech Alert: Searches spiking for these stocks today
- Madrigal Pharmaceuticals price target lowered to $347 from $383 at KeyBanc
Questions or Comments about the article? Write to editor@tipranks.com